Denali Therapeutics’ (DNLI) “Buy” Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note published on Wednesday morning,Benzinga reports. They currently have a $39.00 price target on the stock.

DNLI has been the subject of a number of other reports. Morgan Stanley raised their price target on Denali Therapeutics from $35.00 to $36.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research note on Friday, August 7th. JPMorgan Chase & Co. initiated coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Finally, UBS Group lifted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.15.

Denali Therapeutics Price Performance

NASDAQ:DNLI traded up $0.35 during mid-day trading on Wednesday, reaching $20.07. 1,586,647 shares of the stock were exchanged, compared to its average volume of 1,699,561. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. Denali Therapeutics has a 1-year low of $13.75 and a 1-year high of $27.30. The business has a fifty day moving average price of $20.16 and a 200 day moving average price of $21.27. The firm has a market capitalization of $3.21 billion, a PE ratio of -11.60 and a beta of 1.08.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to analyst estimates of $12.67 million. During the same period in the previous year, the business posted ($0.74) EPS. Research analysts expect that Denali Therapeutics will post -2.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the transaction, the insider directly owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 9.70% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in shares of Denali Therapeutics during the 2nd quarter worth about $360,759,000. Dimensional Fund Advisors LP raised its stake in shares of Denali Therapeutics by 13.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock valued at $51,687,000 after acquiring an additional 317,872 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Denali Therapeutics by 1.9% in the 3rd quarter. Fisher Asset Management LLC now owns 2,460,545 shares of the company’s stock valued at $50,859,000 after acquiring an additional 46,383 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in Denali Therapeutics by 3,490.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after purchasing an additional 1,819,339 shares during the last quarter. Finally, Aberdeen Group plc lifted its holdings in Denali Therapeutics by 13.0% in the 3rd quarter. Aberdeen Group plc now owns 1,520,605 shares of the company’s stock worth $31,431,000 after purchasing an additional 175,124 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s third-quarter results beat expectations: EPS was $0.37 versus the consensus estimate of a $0.27 loss, and revenue was $17.78 million versus a $12.67 million estimate. Denali Therapeutics earnings beat and valuation article
• Positive Sentiment: Commercial momentum and potential catalysts may be lifting sentiment: a report cited nearly fivefold growth in Avlayah sales, broader reimbursement coverage, and multiple upcoming pipeline catalysts. Shares were reported up 7.8% after the earnings release. Zacks report on Denali post-earnings performance
• Positive Sentiment: HC Wainwright initiated coverage with a “Strong Buy” rating, providing a new bullish analyst view. HC Wainwright stock recommendations
• Neutral Sentiment: HC Wainwright’s forecasts show losses continuing in coming years, though its estimates narrow to a $0.14-per-share loss by 2030. The longer-term outlook is therefore still dependent on commercial growth and pipeline progress.
• Neutral Sentiment: A separate report put Denali’s valuation back in focus after the earnings-driven move, suggesting investors may weigh the improved results against the stock’s valuation. Denali earnings and valuation article

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.